Choroidal neovascularization associated with combined hamartoma of retina and retinal pigment epithelium: Multimodal imaging

Indian J Ophthalmol. 2018 Dec;66(12):1866-1868. doi: 10.4103/ijo.IJO_992_18.

Abstract

Combined hamartoma of retina and retinal pigment epithelium (CHRRPE) has been considered as a congenital benign entity with evidence of choroidal neovascularization membranes (CNVM) being associated with it in literature. This case series gives insight into the pathogenesis and the predisposing factors leading to CNVM formation in peripapillary CHRRPE using swept-source optical coherence tomography. In addition, lack of typical markers of CNVM (subretinal fluid/pigment epithelial detachment) in CHRRPE highlights the utility of optical coherence tomography angiography and the subtle optical coherence tomography findings such as "Bridge Sign" that could be instrumental in early diagnosis of CNVM in CHRRPE.

Keywords: Bridge Sign; OCTA in CHRRPE; choroidal neovascularization associated with combined hamartoma of retina and retinal pigment epithelium; combined hamartoma of retina and retinal pigment epithelium.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / therapeutic use
  • Bevacizumab / therapeutic use
  • Choroidal Neovascularization / diagnostic imaging
  • Choroidal Neovascularization / drug therapy
  • Choroidal Neovascularization / etiology*
  • Female
  • Fluorescein Angiography
  • Hamartoma / complications*
  • Hamartoma / diagnostic imaging
  • Hamartoma / drug therapy
  • Humans
  • Intravitreal Injections
  • Male
  • Multimodal Imaging*
  • Retinal Diseases / complications*
  • Retinal Diseases / diagnostic imaging
  • Retinal Diseases / drug therapy
  • Retinal Pigment Epithelium / diagnostic imaging
  • Retinal Pigment Epithelium / pathology*
  • Retrospective Studies
  • Tomography, Optical Coherence
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Young Adult

Substances

  • Angiogenesis Inhibitors
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab